Palatin Technologies (PTN)

$0.09 -0.08 (-44.65%)
Market Cap 2.45M
Revenue (ttm) 4.49M
Net Income (ttm) -29.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -662.36%
Debt to Equity Ratio 0.00
Volume 14,571,800
Avg Vol 3,131,146
Day's Range N/A - N/A
Shares Out 26.01M
Stochastic %K 5%
Beta 0.94
Analysts Strong Sell
Price Target $7.00

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequatel...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 495 2200
Website: palatin.com
Address:
11 Deer Park Drive, Suite 204, Monmouth Junction, United States
kc444
kc444 Feb. 4 at 2:38 PM
$PTN 4 of there medications are close to Phase 3. They’re tackling neuropathy, ulcerative colitis, dry eye disease, and obesity. Even if only 2 of these are successful it will create big moves in the value of this company.
0 · Reply
JOHNB21400
JOHNB21400 Feb. 3 at 8:24 PM
$PTN Volume is building everyday. Maybe 18+ today
0 · Reply
Rollercoaster22
Rollercoaster22 Feb. 2 at 5:35 PM
$PTN Will they release any news this month?
0 · Reply
JOHNB21400
JOHNB21400 Feb. 2 at 4:47 PM
$PTN Running up for the news on twelfth or sooner.
2 · Reply
topstockalerts
topstockalerts Feb. 2 at 4:44 PM
$PTN Making a clean upside move 📈. Volume supports the move and price is trending higher. Momentum traders are engaged.
0 · Reply
Zeusgodmd
Zeusgodmd Jan. 30 at 3:40 PM
$PTN is that kid blowing bubbles or is she farting
0 · Reply
DarkWatcher
DarkWatcher Jan. 28 at 1:12 PM
$PTN this just needs a little push to start floating away!
0 · Reply
DarkWatcher
DarkWatcher Jan. 28 at 12:58 PM
$PTN man… I told a few people here to play IREX… 🤷🏻‍♂️
1 · Reply
DarkWatcher
DarkWatcher Jan. 27 at 8:21 PM
$AITX $PTN $CYBL told you it would be stock worth playing
0 · Reply
DarkWatcher
DarkWatcher Jan. 27 at 6:43 PM
$PTN https://www.youtube.com/watch?v=ESQhptIhD8A I’m coming for those cheapies!
0 · Reply
Latest News on PTN
Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Nov 13, 2025, 3:41 PM EST - 2 months ago

Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:30 AM EST - 2 months ago

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Nov 12, 2025, 12:15 PM EST - 2 months ago

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Nov 6, 2025, 8:00 AM EST - 3 months ago

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Nov 6, 2025, 7:30 AM EST - 3 months ago

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Sep 22, 2025, 7:30 AM EDT - 4 months ago

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Aug 18, 2025, 8:05 AM EDT - 6 months ago

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Palatin Announces 1-for-50 Reverse Stock Split

Aug 8, 2025, 4:00 PM EDT - 6 months ago

Palatin Announces 1-for-50 Reverse Stock Split

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

Jul 15, 2025, 7:30 AM EDT - 7 months ago

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript

May 15, 2025, 6:43 PM EDT - 9 months ago

Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 14, 2025, 7:30 AM EDT - 9 months ago

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 9, 2025, 7:30 AM EDT - 9 months ago

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

Palatin Technologies Announces Closing of Reduced Public Offering

May 8, 2025, 10:19 PM EDT - 9 months ago

Palatin Technologies Announces Closing of Reduced Public Offering

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025, 8:26 PM EDT - 9 months ago

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025, 5:20 PM EDT - 9 months ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:15 AM EDT - 9 months ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 7, 2025, 8:00 AM EDT - 9 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

May 5, 2025, 7:30 AM EDT - 9 months ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 29, 2025, 7:30 AM EDT - 10 months ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 17, 2025, 7:30 AM EDT - 10 months ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Appeals NYSE American Notice of Delisting

Apr 14, 2025, 7:00 AM EDT - 10 months ago

Palatin Appeals NYSE American Notice of Delisting

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 4:01 PM EDT - 10 months ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Apr 10, 2025, 7:30 AM EDT - 10 months ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 31, 2025, 7:30 AM EDT - 11 months ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 28, 2025, 7:30 AM EDT - 11 months ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Mar 25, 2025, 7:30 AM EDT - 11 months ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Feb 15, 2025, 5:41 AM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 13, 2025, 7:30 AM EST - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 10, 2025, 4:00 PM EST - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 7, 2025, 8:00 AM EST - 1 year ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Feb 6, 2025, 7:30 AM EST - 1 year ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Jan 28, 2025, 7:30 AM EST - 1 year ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 19, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Dec 16, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 25, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 12:49 PM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 14, 2024, 7:30 AM EST - 1 year ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 8, 2024, 9:57 AM EST - 1 year ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Nov 4, 2024, 7:30 AM EST - 1 year ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 7, 2024, 4:15 PM EDT - 1 year ago

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 2:55 PM EDT - 1 year ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 28, 2024, 7:30 AM EDT - 1 year ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Aug 22, 2024, 7:30 AM EDT - 1 year ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

kc444
kc444 Feb. 4 at 2:38 PM
$PTN 4 of there medications are close to Phase 3. They’re tackling neuropathy, ulcerative colitis, dry eye disease, and obesity. Even if only 2 of these are successful it will create big moves in the value of this company.
0 · Reply
JOHNB21400
JOHNB21400 Feb. 3 at 8:24 PM
$PTN Volume is building everyday. Maybe 18+ today
0 · Reply
Rollercoaster22
Rollercoaster22 Feb. 2 at 5:35 PM
$PTN Will they release any news this month?
0 · Reply
JOHNB21400
JOHNB21400 Feb. 2 at 4:47 PM
$PTN Running up for the news on twelfth or sooner.
2 · Reply
topstockalerts
topstockalerts Feb. 2 at 4:44 PM
$PTN Making a clean upside move 📈. Volume supports the move and price is trending higher. Momentum traders are engaged.
0 · Reply
Zeusgodmd
Zeusgodmd Jan. 30 at 3:40 PM
$PTN is that kid blowing bubbles or is she farting
0 · Reply
DarkWatcher
DarkWatcher Jan. 28 at 1:12 PM
$PTN this just needs a little push to start floating away!
0 · Reply
DarkWatcher
DarkWatcher Jan. 28 at 12:58 PM
$PTN man… I told a few people here to play IREX… 🤷🏻‍♂️
1 · Reply
DarkWatcher
DarkWatcher Jan. 27 at 8:21 PM
$AITX $PTN $CYBL told you it would be stock worth playing
0 · Reply
DarkWatcher
DarkWatcher Jan. 27 at 6:43 PM
$PTN https://www.youtube.com/watch?v=ESQhptIhD8A I’m coming for those cheapies!
0 · Reply
DarkWatcher
DarkWatcher Jan. 27 at 4:12 AM
$PTN the flag is almost to the end… lower volume tho…. I’m also waiting for nfxl and Iren to break past their resistance… 😅
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 5:46 PM
$PTN
0 · Reply
HaroldZoid
HaroldZoid Jan. 23 at 8:36 PM
$PTN Disgusting to see what's happened here.
0 · Reply
Rollercoaster22
Rollercoaster22 Jan. 22 at 5:02 PM
$PTN
0 · Reply
JOHNB21400
JOHNB21400 Jan. 22 at 4:52 PM
$PTN Here we go. Back to the 40 target.
1 · Reply
Rollercoaster22
Rollercoaster22 Jan. 22 at 4:50 PM
$PTN Beyond
0 · Reply
Stocks787
Stocks787 Jan. 22 at 12:02 PM
$PTN $80.00 plus 🚀
0 · Reply
Rollercoaster22
Rollercoaster22 Jan. 22 at 11:38 AM
$PTN Vanguard bought 18980 shares in December. Very
0 · Reply
DarkWatcher
DarkWatcher Jan. 20 at 2:52 AM
$PTN
1 · Reply
DarkWatcher
DarkWatcher Jan. 19 at 8:28 PM
$PTN 🔥 watch and see! 🔥🚀 $CYBL $GTVH
1 · Reply
MSR67
MSR67 Jan. 17 at 5:29 AM
$PTN this stock is dead weight lol
1 · Reply
DarkWatcher
DarkWatcher Jan. 16 at 2:32 PM
$PTN what’s up? Is ST glitching?
0 · Reply